Outcomes of a Formal Hematopoietic Cell Transplantation (HCT) Survivorship Program on Screening for Late Effects

Advances in the treatment of hematologic malignancies, allogeneic hematopoietic cell transplantation (HCT), and supportive care continue to improve post-HCT outcomes, and the number of long-term HCT survivors in the past decade has dramatically increased.1,2 With improved post-HCT survival, it is increasingly important to consider late-treatment effects from chemotherapy and/or radiation and chronic graft-vs-host disease (GVHD) which may lead to decrements in quality of life (QOL) and survival,3 –5 especially since life expectancy post-HCT remains lower than that of the general population.

Source: Biology of Blood and Marrow Transplantation - April 27, 2024 Category: Hematology Authors: Richard A. Newcomb, Lucy Gao, Julie Vanderklish, Alexandra Tse, Meredith Saylor, Colleen Danielson, Nisha Wali, Matthew Frigault, Steven McAfee, Thomas Spitzer, Zachariah DeFilipp, Yi-Bin Chen, Hermioni L. Amonoo, Areej El-Jawahri Source Type: research